drugset / Trial / NCT03002259

Dexamethasone for Cardiac Surgery-II Trial

NCT03002259 ↗

Phase 4 Unknown 1956 enrolled Bayside Health UMC Utrecht · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Background. Numerous studies have investigated high-dose corticosteroids in cardiac surgery, but with mixed results leading to ongoing variations in practice around the world. The Dexamethasone for Cardiac Surgery-II Trial (DECS-II) is a study comparing high-dose dexamethasone with placebo in patients undergoing cardiac surgery. Methods. We discuss the rationale for conducting DECS-II, a 2800-patient, pragmatic, multicenter, assessor-blinded, randomized trial in cardiac surgery, and the features of the DECS-II study design (objectives, end points, target population, balanced clusters based on practice preference with post-randomization consent, treatments, patient follow-up and analysis). Conclusions. The DECS-II Trial will use a novel, efficient trial design to evaluate whether high-dose dexamethasone has a patient-centered benefit of enhancing recovery and increasing the number of days at home after cardiac surgery.

Timeline

Start
2018-09-01
Primary completion
2023-01-31
Completion
2023-01-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexamethasone Small molecule 1 mg/kg Intravenous

Indications